Grade ≥ 3 diarrhoea · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea ‐ seribantumab compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Toxicity: grade 3 or 4 nausea ± vomiting · treatment of relapsed epithelial ovarian cancer
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 nausea ± vomiting compared with chemotherapy alone (low certainty).
1 finding from 1 review
Toxicity: grade 3 or 4 fatigue · treatment of relapsed epithelial ovarian cancer
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 fatigue compared with chemotherapy alone (low certainty).
1 finding from 1 review
Toxicity: grade 3 or 4 hypokalaemia · treatment of relapsed epithelial ovarian cancer
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 hypokalaemia compared with chemotherapy alone (low certainty).
1 finding from 1 review
Quality of life · treatment of relapsed epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival† · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy probably leads to lower overall survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.6 [0.45, 0.81]
324 participants
Moderate
Progression‐free survival · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.69 [0.52, 0.92]
324 participants
Moderate
Tumour response · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.71 [0.96, 3.03]
324 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
1 finding from 1 review
RR 0.68 [0.09, 5.32]
324 participants
Low
Mean CD4% Increase During Chemo · Kaposi sarcoma in children with HIV‐1 infection
1 finding from 1 review
no estimate extracted
48 participants
Very low
All‐cause mortality · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes mortality compared with ART (very low certainty).
1 finding from 1 review
RR 0.72 [0.37, 1.43]
50 participants
Very low
Complete response · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete Response to Tx compared with ART (very low certainty).
1 finding from 1 review
RR 1.57 [0.22, 11.34]
89 participants
Very low
Complete response plus partial response Length of · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete/Partial Response to Tx compared with ART (very low certainty).
1 finding from 1 review
RR 5.75 [1.59, 20.73]
39 participants
Very low
Complete Among Known Outcome · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete Among Known Outcome compared with ART (very low certainty).
1 finding from 1 review
RR 0.84 [0.48, 1.48]
26 participants
Very low
Complete/Partial Among Known Outcome · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete/Partial Among Known Outcome compared with ART (very low certainty).
1 finding from 1 review
RR 1.13 [0.67, 1.89]
26 participants
Very low
Overall survival ‐ 5FU · advanced pancreatic cancer
Various types of chemotherapy probably leads to higher overall survival ‐ 5FU compared with gemcitabine (moderate certainty).
1 finding from 1 review
Overall survival ‐ FOLFIRINOX · advanced pancreatic cancer
Various types of chemotherapy probably leads to lower overall survival ‐ FOLFIRINOX compared with gemcitabine (moderate certainty).
1 finding from 1 review
Overall survival ‐ Fixed dose rate gemcitabine · advanced pancreatic cancer
Various types of chemotherapy leads to lower overall survival ‐ Fixed dose rate gemcitabine compared with gemcitabine (high certainty).
1 finding from 1 review
Overall survival ‐ CO‐101 · advanced pancreatic cancer
Various types of chemotherapy showed no clear difference in overall survival ‐ CO‐101 compared with gemcitabine (moderate certainty).
1 finding from 1 review
Overall survival ‐ ZD9331 · advanced pancreatic cancer
Various types of chemotherapy showed no clear difference in overall survival ‐ ZD9331 compared with gemcitabine (moderate certainty).
1 finding from 1 review